Alector, Inc.
HealthcareNASDAQ:ALEC · NASDAQ Global Select
-$0.04 today
Vol 0.26M · Avg 0.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-466.3%
avg -68.0%
ROIC
-62.5%
avg -30.3%
ROA
-48.7%
avg -23.9%
Analysis
ROA is currently the strongest return metric at -48.7% versus its period average of -23.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Arnon Rosenthal | Co-Founder, Chief Executive Officer & Director | $1.01M | — | 70 | $2.45M | 2.21% |
Giacomo Salvadore | Chief Medical Officer | $752,171.00 | — | — | — | — |
Neil Berkley | CFO & Chief Business Officer | $705,122.00 | — | 52 | $399,260.00 | 0.36% |
Hua Long DABT | Senior VP & Head of Research | — | — | — | — | — |
Clare Hunt | Chief People & Places Officer | — | — | — | — | — |
Katie Hogan | Senior Director of Corporate Communication & Investor Relations | — | — | — | — | — |
Kristina Cutter | Chief Development Officer | — | — | — | — | — |
Danielle Pasqualone | General Counsel | — | — | — | — | — |
Eric Brown | Director of Antibody Discovery & Protein Engineering | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
18
$775,090.79
Net Sentiment
$775,090.79
Net selling
Most Active
Wong-Sarad Grace
8 transactions
1–10 of 18
Analysis
Insiders reported 0 buys worth $0.00 and 18 sells worth $775,090.79 over the last 12 months. That adds up to net selling of $775,090.79. Wong-Sarad Grace was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +78.1% | -13.3% (10yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +78.1% over three years. Forward estimates point to Revenue at -13.3% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Fate Therapeutics, Inc.
NASDAQ:FATE
$240.11M
Nkarta, Inc.
NASDAQ:NKTX
$204.62M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
PepGen Inc.
NASDAQ:PEPG
$101.68M
Vor Biopharma Inc.
NASDAQ:VOR
$98.42M
Cassava Sciences, Inc.
SAVA
$63.77M
Applied Therapeutics, Inc.
APLT
$14.86M
Who manages ALEC?
Alector, Inc. (ALEC) lists 9 active executives. The top listed executive is Hua Long DABT, Senior VP & Head of Research.
Are ALEC insiders buying or selling?
Recent insider activity shows net selling of $4.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.